{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:20:22Z","timestamp":1778772022881,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00280-019-03944-w","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T10:02:56Z","timestamp":1568023376000},"page":"1115-1123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer"],"prefix":"10.1007","volume":"84","author":[{"given":"Saichun","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"issue":"11","key":"3944_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jjco\/hyv119","volume":"45","author":"TC Huang","year":"2015","unstructured":"Huang TC, Hsu CH, Lin CC, Tu YK (2015) Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. Jpn J Clin Oncol 45(11):1023\u20131028. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyv119","journal-title":"Jpn J Clin Oncol"},{"issue":"22","key":"3944_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, Group C (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074\u20132084","journal-title":"N Engl J Med"},{"issue":"11","key":"3944_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/cgt.2014.55","volume":"21","author":"Y Zhen","year":"2014","unstructured":"Zhen Y, Guanghui L, Xiefu Z (2014) Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther 21(11):491\u2013497. \n                    https:\/\/doi.org\/10.1038\/cgt.2014.55","journal-title":"Cancer Gene Ther"},{"key":"3944_CR4","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.2147\/OTT.S111691","volume":"9","author":"J Song","year":"2016","unstructured":"Song J, Shi W, Zhang Y, Sun M, Liang X, Zheng S (2016) Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis. OncoTargets Ther 9:6257\u20136263. \n                    https:\/\/doi.org\/10.2147\/OTT.S111691","journal-title":"OncoTargets Ther"},{"issue":"7","key":"3944_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.prp.2018.04.017","volume":"214","author":"W Yu","year":"2018","unstructured":"Yu W, Yang X, Chu L, Zhao K, Chen H, Xiang J, Zhang Y, Li H, Zhao W, Sun M, Wei Q, Fu X, Xie C, Zhu Z (2018) Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients. Pathol Res Pract 214(7):1017\u20131023. \n                    https:\/\/doi.org\/10.1016\/j.prp.2018.04.017","journal-title":"Pathol Res Pract"},{"issue":"11","key":"3944_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","volume":"3","author":"M Suntharalingam","year":"2017","unstructured":"Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH (2017) Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol 3(11):1520\u20131528. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2017.1598","journal-title":"JAMA Oncol"},{"issue":"2","key":"3944_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/COC.0b013e318271b14f","volume":"37","author":"YY Janjigian","year":"2014","unstructured":"Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH (2014) Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. Am J Clin Oncol 37(2):126\u2013130. \n                    https:\/\/doi.org\/10.1097\/COC.0b013e318271b14f","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"3944_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/cncr.25602","volume":"117","author":"DH Ilson","year":"2011","unstructured":"Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D (2011) A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117(7):1409\u20131414. \n                    https:\/\/doi.org\/10.1002\/cncr.25602","journal-title":"Cancer"},{"issue":"1\u20132","key":"3944_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","volume":"45","author":"Z Mazorra","year":"2018","unstructured":"Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T (2018) Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol 45(1\u20132):18\u201326. \n                    https:\/\/doi.org\/10.1053\/j.seminoncol.2018.04.008","journal-title":"Semin Oncol"},{"key":"3944_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1479-5876-10-249","volume":"10","author":"L Zhao","year":"2012","unstructured":"Zhao L, He LR, Xi M, Cai MY, Shen JX, Li QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, Xie D, Liu MZ (2012) Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. J Transl Med 10:249. \n                    https:\/\/doi.org\/10.1186\/1479-5876-10-249","journal-title":"J Transl Med"},{"issue":"3","key":"3944_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/cas.13481","volume":"109","author":"K Kato","year":"2018","unstructured":"Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K (2018) Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: a phase I study. Cancer Sci 109(3):785\u2013793. \n                    https:\/\/doi.org\/10.1111\/cas.13481","journal-title":"Cancer Sci"},{"key":"3944_CR12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2147\/ott.s50945","volume":"6","author":"J Liang","year":"2013","unstructured":"Liang J, Mingyan E, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, Chen D, Zou S, Lu N, Perez-Rodriguez R, Zheng J, Wang L (2013) Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. OncoTargets Ther 6:1589\u20131596. \n                    https:\/\/doi.org\/10.2147\/ott.s50945","journal-title":"OncoTargets Ther"},{"key":"3944_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.10.005","volume":"88","author":"Junior G de Castro","year":"2018","unstructured":"de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araujo Lima Franca B, Del Giglio A, Lazaretti NS, Alvares MN, Pedrini JL, Kussumoto C, de Matos Neto JN, Forones NM, Fernandes Junior HJ, Borges G, Girotto G, da Silva I, Maluf-Filho F, Skare NG (2018) A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial. Eur J Cancer 88:21\u201330. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.10.005","journal-title":"Eur J Cancer"},{"issue":"2","key":"3944_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/SLA.0b013e31815aaadf","volume":"247","author":"C Mariette","year":"2008","unstructured":"Mariette C, Piessen G, Briez N, Triboulet JP (2008) The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 247(2):365\u2013371. \n                    https:\/\/doi.org\/10.1097\/SLA.0b013e31815aaadf","journal-title":"Ann Surg"},{"issue":"9","key":"3944_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Group Cs, (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090\u20131098. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00040-6","journal-title":"Lancet Oncol"},{"issue":"27","key":"3944_CR16","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/jco.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D\u2019Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J, Group AMETSC (2018) Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a Phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 36(27):2796\u20132803. \n                    https:\/\/doi.org\/10.1200\/jco.2018.79.1483","journal-title":"J Clin Oncol"},{"issue":"4","key":"3944_CR17","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10637-011-9735-0","volume":"30","author":"KL Zhao","year":"2012","unstructured":"Zhao KL, Hu XC, Wu XH, Fu XL, Fan M, Jiang GL (2012) A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Invest New Drugs 30(4):1585\u20131590. \n                    https:\/\/doi.org\/10.1007\/s10637-011-9735-0","journal-title":"Invest New Drugs"},{"issue":"8","key":"3944_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4161\/cbt.19849","volume":"13","author":"M Ramos-Suzarte","year":"2012","unstructured":"Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB, Ramos TC (2012) Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 13(8):600\u2013605. \n                    https:\/\/doi.org\/10.4161\/cbt.19849","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3944_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10147-013-0564-3","volume":"19","author":"NY Ma","year":"2014","unstructured":"Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Lai ST, Jiang GL, Zhao KL (2014) Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. Int J Clin Oncol 19(2):297\u2013302. \n                    https:\/\/doi.org\/10.1007\/s10147-013-0564-3","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"3944_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3978\/j.issn.2072-1439.2011.08.02","volume":"4","author":"Y Ling","year":"2012","unstructured":"Ling Y, Chen J, Tao M, Chu X, Zhang X (2012) A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. J Thorac Dis 4(1):58\u201362. \n                    https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2011.08.02","journal-title":"J Thorac Dis"},{"key":"3944_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OTT.S89592","volume":"9","author":"C Wang","year":"2016","unstructured":"Wang C, Fu X, Cai X, Wu X, Hu X, Fan M, Xiang J, Zhang Y, Chen H, Jiang G, Zhao K (2016) High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. OncoTargets Ther 9:117\u2013122. \n                    https:\/\/doi.org\/10.2147\/OTT.S89592","journal-title":"OncoTargets Ther"},{"issue":"5","key":"3944_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3892\/mco.2015.606","volume":"3","author":"JH Guo","year":"2015","unstructured":"Guo JH, Chen MQ, Chen C, Lu HJ, Xu BH (2015) Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma. Mol Clin Oncol 3(5):1135\u20131138. \n                    https:\/\/doi.org\/10.3892\/mco.2015.606","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"3944_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12094-015-1406-8","volume":"18","author":"J Jia","year":"2016","unstructured":"Jia J, Cui Y, Lu M, Wang X, Li J, Li J, Li Y, Zhang X, Gao J, Zhou J, Lu Z, Gong J, Yu J, Sun Z, Liu C, Shen L, Zhang X (2016) The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clin Transl Oncol 18(6):592\u2013598. \n                    https:\/\/doi.org\/10.1007\/s12094-015-1406-8","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"3944_CR24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/cas.12894","volume":"107","author":"M Lu","year":"2016","unstructured":"Lu M, Wang X, Shen L, Jia J, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Zhou J, Zhang X (2016) Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: a single centre prospective phase II trial. Cancer Sci 107(4):486\u2013490. \n                    https:\/\/doi.org\/10.1111\/cas.12894","journal-title":"Cancer Sci"},{"issue":"9","key":"3944_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ejso.2017.03.001","volume":"43","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G, Barni S (2017) Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies. Eur J Surg Oncol 43(9):1607\u20131616. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2017.03.001","journal-title":"Eur J Surg Oncol"},{"key":"3944_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3644-2","author":"J Li","year":"2018","unstructured":"Li J, Yan H (2018) Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol. \n                    https:\/\/doi.org\/10.1007\/s00280-018-3644-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3944_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3727\/096504017X14913452320194","volume":"26","author":"I Kainis","year":"2018","unstructured":"Kainis I, Syrigos N, Kopitopoulou A, Gkiozos I, Filiou E, Nikolaou V, Papadavid E (2018) Erlotinib-associated rash in advanced non-small cell lung cancer: relation to clinicopathological characteristics, treatment response, and survival. Oncol Res 26(1):59\u201369. \n                    https:\/\/doi.org\/10.3727\/096504017X14913452320194","journal-title":"Oncol Res"},{"key":"3944_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2015.11.022","volume":"55","author":"M Steffens","year":"2016","unstructured":"Steffens M, Paul T, Hichert V, Scholl C, von Mallek D, Stelzer C, Sorgel F, Reiser B, Schumann C, Rudiger S, Boeck S, Heinemann V, Kachele V, Seufferlein T, Stingl J (2016) Dosing to rash?\u2014the role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. Eur J Cancer 55:131\u2013139. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2015.11.022","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03944-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T23:09:30Z","timestamp":1599520170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03944-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3944"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03944-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}